摘要
目的:探讨单纯Hyper-CVAD方案与Hyper-CVAD方案联合自体造血干细胞移植一线巩固治疗淋巴母细胞淋巴瘤(lymphoblastic lymphoma,LL)的疗效。方法:回顾性分析26例青少年和成人初治采用改良Hyper-CVAD方案的LL患者资料。其中,22例不伴骨髓受侵的患者中,11例接受单纯改良Hyper-CVAD方案治疗,另外11例接受改良Hyper-CVAD方案联合HDT/AH-SCT巩固治疗。结果:全组61.5%(16/26)的患者初治达完全缓解(complete remission,CR)或不确定的CR(unconfirmed CR,CRu),中位随访29.5个月,5年的总生存(overall survival,OS)率和无进展生存(progress-free survival,PFS)率分别为66.8%和50.2%。22例无骨髓受侵的患者中,单纯Hyper-CVAD组与联合HDT/AHSCT组的5年OS率分别为60.0%和70.7%(P=0.438),5年PFS率分别为43.6%和62.3%(P=0.209),均无统计学差异。单因素预后分析结果显示,初治缓解后1年内疾病进展或复发与预后不良相关(P=0.012)。结论:改良Hyper-CVAD方案是青少年和成人LL一线有效的治疗方案。对于无骨髓侵犯的患者,单纯改良Hyper-CVAD已能取得较好疗效,联合HDT/AHSCT巩固治疗未能进一步改善预后。
Objectives: This study evaluated the efficiency of HyperCVAD regimen with or without high-dose therapy (HDT) combined with autologous hematopoietic stem cell transplantation (AHSCT) in lymphoblastic lymphoma (LL). Methods:Data of 26 adolescent and adult LL patients were retrospectively analyzed. These patients were initially treated with the modified HyperCVAD reg-imen in a basic institution. Except 4 of the total 26 patients who suffered bone-marrow involvements, 11 patients received consolidation treatment of HDT/AHSCT, and the other 11 did not. Results:Of the total patients, 61.5%achieved complete remission (CR) or uncon-firmed CR. With a median follow-up period of 29.5 months, the 5-year overall survival (OS) and progress-free survival (PFS) rates were 66.8% and 50.2%, respectively. Of the 22 patients without bone marrow involvement, the corresponding 5-year OS rates were 60.0%and 70.7%in the patients treated with the HyperCVAD regimen alone and in those who received HDT/AHSCT as consolidation therapy (P=0.438), with 5-year PFS rates of 43.6% and 62.3%, respectively (P=0.209). Disease progression or relapse within a year was identified as the only significant prognostic factor for OS in univariate analysis. Conclusion:The HyperCVAD regimen is an effec-tive initial therapy for adolescent and adult LL patients. For patients without bone marrow involvement, the HyperCVAD regimen com-bined with HDT/AHSCT is not superior over the HyperCVAD regimen alone.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2015年第1期13-18,共6页
Chinese Journal of Clinical Oncology
基金
国家"九.五"攻关课题(编号:A20199610396-906-01-12)
卫生部优秀青年科技人材专项基金(编号:B121994002)
人事部归国留学人员启动基金(编号:B311994001)
高等学校博士学科点专项科研基金(编号:20010023018
20050023045
B201995002)
霍英东高等院校青年教师基金(编号:B231996001)资助~~